Dechra Pharmaceuticals PLC Annual Report and Accounts for the year ended 30 June 2009 Consolidated Statement of Changes in Shareholders Equity For the year ended 30 June 2009 Foreign Issued Share currency share premium Hedging translation Merger Retained capital account reserve reserve reserve earnings Total Year ended 30 June 2008 000 000 000 000 000 000 000 At 1 July 2007 528 28,041 71 1,770 240 30,508 Profit for the period 8,318 8,318 Fair value gains on derivative financial instruments 352 352 Exchange differences on translation of foreign operations 2,415 2,415 Net loss on hedge of net investment in foreign operations 807 807 Total recognised income and expense for the period 352 1,608 8,318 10,278 Dividends paid 4,420 4,420 Share-based payments 1,184 1,184 Shares issued 124 35,636 35,760 Share issue expenses 1,511 1,511 At 30 June 2008 652 62,166 281 1,608 1,770 5,322 71,799 Year ended 30 June 2009 At 1 July 2008 652 62,166 281 1,608 1,770 5,322 71,799 Profit for the period 11,303 11,303 Fair value losses on derivative financial instruments 1,024 1,024 Exchange differences on translation of foreign operations 4,866 4,866 Net loss on hedge of net investment in foreign operations 1,532 1,532 Recycled to intangible assets 40 40 Recycled to income statement 256 256 Total recognised income and expense for the period 984 3,078 11,303 13,397 Dividends paid 5,565 5,565 Share-based payments 780 780 Shares issued 4 271 275 At 30 June 2009 656 62,437 703 4,686 1,770 11,840 80,686 Hedging Reserve The hedging reserve represents the cumulative fair value gains or losses on derivative financial instruments for which hedge accounting has been applied.
Foreign Currency Translation Reserve The foreign currency translation reserve contains exchange differences on the translation of subsidiaries with a functional currency other than Sterling and exchange gains or losses on the translation of liabilities that hedge the Companys net investment in foreign subsidiaries.
Merger Reserve The merger reserve represents the excess of fair value over nominal value of shares issued in consideration for the acquisition of subsidiaries where statutory merger relief has been applied in the financial statements of the Parent Company.
